Trials / Completed
CompletedNCT06193031
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study of C16TR for Inhalation to Determine Its Safety, Tolerability, and Pharmacokinetics With an Open-label Tyvaso® Cohort in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Insmed Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to determine the safety and tolerability of escalating doses of C16TR for inhalation in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | C16TR | Administered as inhalation using a Philips Micro device inhaler. |
| DRUG | Placebo | Phosphate buffered saline (PBS) administered using Philips Micro device inhaler. |
| DRUG | Tyvaso® | Administered as inhalation. |
Timeline
- Start date
- 2015-11-17
- Primary completion
- 2015-12-18
- Completion
- 2015-12-18
- First posted
- 2024-01-05
- Last updated
- 2024-01-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06193031. Inclusion in this directory is not an endorsement.